JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

Utilization of Artificial Intelligence in Pharmaceutical Sciences for Teaching, Learning, and Clinical Practice

Syamala B[1], Govindarao Kamala*[2], Harika G[1], A V D S Prajna M[1], Sindhu Sri Durga N[1], Jahnavi Ketha[1]

[1] *UG Scholar, Department of Pharmaceutical Chemistry, Koringa College of Pharmacy, Korangi, Kakinada, Andhra Pradesh, India*
[2] *Vice-Principal and Professor, Department of Pharmaceutical Chemistry, Koringa College of Pharmacy, Korangi, Kakinada, Andhra Pradesh, India*

Publication history: Received on 18th November 2025; Revised on 28th December 2025; Accepted on 3rd January 2026

Article DOI: 10.69613/dw5jnw67

Abstract: The utilization of Artificial Intelligence (AI) in pharmaceutical sciences marks a transformative shift from traditional empirical methods to data-driven, precision-oriented methodologies. Computational frameworks, including machine learning, deep learning, and natural language processing, now facilitate the analysis of high-dimensional biological data, the automation of complex pharmaceutical processes, and the optimization of clinical outcomes. In drug discovery, AI-driven architectures enable the rapid identification of lead compounds and the prediction of molecular interactions with unprecedented accuracy, significantly reducing the temporal and financial constraints of the development cycle. Within the domain of pharmaceutics, artificial neural networks and genetic algorithms have replaced iterative trial-and-error approaches in formulation design, allowing for the precise modulation of drug release profiles and the development of personalized 3D-printed dosage forms. Furthermore, the clinical landscape is being reshaped by intelligent decision support systems and robotic automation, which mitigate medication errors and enhance patient safety. Graduate pharmacy education must evolve to include rigorous training in algorithmic literacy and digital therapeutics as these technologies become deeply embedded in the healthcare infrastructure. This transition ensures that the next generation of pharmacists possesses the technical competency required to navigate a landscape where human expertise is augmented by computational intelligence. The synergy between pharmaceutical expertise and advanced algorithms is not merely an incremental improvement but a fundamental restructuring of how therapeutic agents are discovered, formulated, and managed in clinical environments.

Keywords: Artificial Intelligence; Computational Pharmaceutics; Molecular Modeling; Clinical Decision Support; Pharmacy Education

1. Introduction

The application of computational intelligence within the medical and pharmaceutical sectors involves advanced mathematical modeling and biological data processing. It operates through the deployment of intricate algorithms designed to decode the non-linear complexities inherent in massive repositories of healthcare data, thereby generating insights that facilitate superior clinical outcomes. These computational systems possess the capability to emulate high-level cognitive processes specifically pattern recognition, logical deduction, and autonomous decision-making which for decades remained the exclusive domain of trained medical professionals [1]. These architectures allow for the identification of subtle correlations between chemical structures and biological responses by processing high-dimensional data at speeds unattainable by human cognition. The integration of these tools has moved the field beyond mere data collection toward a proactive state where predictive analytics inform every stage of therapeutic development, ensuring that medical decisions are rooted in quantitative evidence rather than qualitative observation.

Historically, the integration of computer-aided methodologies into pharmacy practice was relatively rudimentary and limited in scope. During the 1980s, technological applications primarily served auxiliary functions, focusing on the digitization of administrative workflows such as inventory procurement, billing, and the basic electronic entry of prescriptions. These early iterations lacked the predictive power or the cognitive "intelligence" required to assist in clinical judgment, serving instead as digital filing systems that replaced manual record-keeping with electronic databases [2]. The constraints of early hardware and the lack of complex algorithms meant that the pharmacist's role remained largely manual, centered on the physical preparation and dispensing of medications. However, as computational power grew and data storage became more accessible, the potential for technology to impact the clinical core of the profession became evident, leading to a gradual departure from purely clerical applications toward clinical decision support.

* Corresponding author: Govindarao Kamala

In this new paradigm, the focus has shifted from "one-size-fits-all" pharmacotherapy to individualized, data-driven interventions [3]. Pharmaceutical care is increasingly governed by high-fidelity data analytics and predictive modeling, which utilize a patient's genomic, proteomic, and lifestyle data to guide therapeutic choices. This transition is fueled by the availability of "big data" ranging from electronic health records to large-scale clinical trials which AI models can aggregate to predict how specific populations or individuals will respond to a particular treatment. This capability marks a departure from empirical medicine toward a more certain, evidence-based practice where risks are identified before the first dose is administered, thereby significantly improving the safety profile of complex drug regimens [4,5].

Artificial intelligence in this context functions as a transformative catalyst for optimizing the entire pharmaceutical lifecycle, from initial molecular design to post-marketing surveillance. In the pre-clinical phase, computational models are employed to predict idiosyncratic drug responses and evaluate the probability of adverse outcomes. This includes the early-stage assessment of potential toxicity, which is critical for reducing the high failure rates typically observed in drug development pipelines. AI architectures enable the precise modeling of pharmacokinetic and pharmacodynamic parameters, allowing for the simulation of drug behavior across diverse physiological conditions without the immediate need for human or animal subjects [6]. These models provide a virtual laboratory where molecular interactions are scrutinized with microscopic accuracy, ensuring that only the most viable drug candidates proceed to clinical evaluation, thus saving time and financial resources while upholding ethical standards in research.

Apart from laboratory research, the impact of AI is profoundly visible in the operational and clinical aspects of hospital pharmacy. Modern healthcare environments leverage AI-driven architectures to facilitate the automation of complex workflows, ranging from high-precision robotic dispensing units to real-time clinical decision support systems. These systems provide a critical safety net by alerting practitioners to potential drug-drug interactions, identifying dosing discrepancies, or flagging contraindications in patients with multi-organ failure or complex comorbidities [7, 8]. These technologies enhance the safety and efficiency of medication management by mitigating the risk of human error in high-pressure environments. These systems do not merely provide alerts; they act as intelligent assistants that suggest therapeutic alternatives and dosing adjustments based on real-time physiological changes in the patient, ensuring that pharmaceutical care is as dynamic as the patient's condition [9, 10].

This technological transition necessitates a fundamental and urgent reassessment of graduate pharmacy curricula. As the profession moves away from traditional dispensing roles and toward a model centered on clinical data science and therapeutic optimization, the educational foundation must evolve accordingly. It is essential to ensure that graduate students are equipped with the technical competency to navigate an environment increasingly characterized by industrial automation and algorithmic decision-making. Preparing the next generation of pharmacists requires a curriculum that integrates computational literacy with pharmaceutical expertise. This evolution ensures that future practitioners can critically evaluate AI-generated outputs, manage digital therapeutics, and lead the implementation of new technologies. Ultimately, this educational shift ensures that pharmacists remain essential leaders in a data-driven healthcare ecosystem, capable of bridging the gap between advanced technology and patient-centered care.

2. Taxonomy of Computational Intelligence in Pharmaceutical Sciences

The classification of AI methodologies within the pharmaceutical domain is essential for determining the appropriate algorithmic approach for specific research or clinical challenges. These methodologies are generally categorized based on their learning architecture and their specific application within the drug development and delivery process.

2.1. Learning Methods and Algorithms

The effectiveness of a computational model is contingent upon its learning paradigm, which dictates how the system processes input data to generate predictive outputs or identify latent structures.

2.1.1. Supervised Learning Architectures

Supervised learning remains the most prevalent approach in pharmaceutical research, requiring the use of annotated datasets where the input variables are mapped to known outcomes. This methodology is indispensable for Quantitative Structure-Activity Relationship (QSAR) modeling, where the chemical features of a molecule are used to predict its biological activity or affinity for a specific target receptor [11]. Supervised models such as Support Vector Machines (SVM) and Random Forests are extensively employed in toxicity prediction and the estimation of pharmacokinetic parameters, allowing researchers to filter out suboptimal candidates early in the drug development pipeline [12].

Table 1. Classification of AI Learning Paradigms and Pharmaceutical Use Cases

Learning Paradigm	Computational Objectives	Algorithms	Pharmaceutical Applications
Supervised Learning	Mapping input features to defined, labeled output variables.	Support Vector Machines (SVM), Random Forest, Gradient Boosting	QSAR modeling, toxicity prediction (ADMET), biomarker identification.
Unsupervised Learning	Identifying latent structures or clusters within unlabeled datasets.	K-Means Clustering, Principal Component Analysis (PCA)	Patient stratification, disease phenotype clustering, lead compound grouping.
Reinforcement Learning	Optimizing decision sequences through agent-environment feedback.	Q-Learning, Deep Deterministic Policy Gradient (DDPG)	De novo molecular design, dynamic dosage optimization, clinical trial adaptive scheduling.
Deep Learning	Processing hierarchical features via multi-layered neural architectures.	Convolutional Neural Networks (CNN), Recurrent Neural Networks (RNN)	Protein structure prediction (AlphaFold), medical imaging analysis, NLP for EHR extraction.

2.1.2. Unsupervised Learning and Pattern Discovery

In contrast to supervised methods, unsupervised learning involves the analysis of unlabeled data to discover inherent patterns or groupings. In graduate pharmaceutical research, this is particularly valuable for biomarker discovery and the clustering of disease phenotypes based on genomic or proteomic profiles. Principal Component Analysis (PCA) is frequently utilized to reduce the dimensionality of complex biological datasets, enabling the identification of key variables that contribute to drug resistance or therapeutic efficacy without the need for prior classification [13, 14].

2.1.3. Reinforcement Learning in Dynamic Optimization

Reinforcement learning operates on the principle of agent-based interaction within a defined environment, where the model learns through a system of rewards and penalties. This approach is increasingly applied to de novo drug design, where algorithms autonomously generate molecular structures and refine them based on predicted binding scores. Additionally, reinforcement learning facilitates the optimization of dosing regimens in critical care settings, where the algorithm must adapt to the fluctuating physiological state of a patient in real-time to maintain therapeutic levels while minimizing adverse effects [15].

2.2. Domain-Specific Classifications in Pharmacy

The application of AI is further classified by the specific pharmaceutical discipline it serves, ranging from the initial stages of medicinal chemistry to the final stages of clinical dispensing.

2.2.1. Medicinal Chemistry and Molecular Generative Models

Modern medicinal chemistry leverages Deep Learning (DL) and Generative Adversarial Networks (GANs) to navigate the vast chemical space. Unlike traditional screening, these models can "imagine" novel chemical entities with specific physicochemical properties. The advent of tools like AlphaFold has revolutionized protein structure prediction, allowing for the rapid identification of druggable pockets on previously "undruggable" targets, thereby streamlining the hit-to-lead optimization process [16].

2.2.2. Computational Pharmaceutics and Process Analytical Technology

In the realm of pharmaceutics, Artificial Neural Networks (ANNs) have become a standard tool for modeling the complex, non-linear relationships between formulation variables and drug release kinetics. This is particularly relevant in the development of controlled-release systems, where minor adjustments in excipient concentrations can significantly alter the therapeutic profile. Genetic Algorithms (GAs) are also employed to optimize manufacturing parameters and ensure consistency in large-scale production, aligning with the regulatory shift toward Process Analytical Technology (PAT) and Quality by Design (QbD) [17].

2.2.3. Pharmacological Modeling and Clinical Analytics

Pharmacology utilizes advanced computational models to predict Adverse Drug Reactions (ADRs) by analyzing electronic health records and post-marketing surveillance data. Natural Language Processing (NLP) allows for the extraction of relevant clinical data from unstructured medical notes, facilitating the identification of rare side effects that may not have been captured during clinical

trials. In the hospital setting, these models power intelligent chatbots and patient monitoring systems that provide personalized counseling and ensure adherence to complex therapeutic regimens [13].

3. Applications in Specialized Pharmaceutical Areas

The implementation of computational intelligence has progressed from theoretical modeling to practical integration across various pharmacy specializations. This evolution is particularly evident in how high-dimensional data is leveraged to solve complex biological and operational challenges.

3.1. Drug Discovery and Accelerated Molecular Development

The traditional drug discovery pipeline is notoriously protracted and capital-intensive, often spanning over a decade with high attrition rates. AI-driven methodologies have begun to compress these timelines by automating the identification and optimization of lead compounds.

3.1.1. Deep Learning for Virtual Screening and Docking

Advanced deep learning architectures allow for the rapid virtual screening of chemical libraries containing billions of molecules. Researchers can predict the binding affinity of a ligand to a protein target with significantly higher precision than classical force-field-based methods by utilizing convolutional neural networks (CNNs). For instance, deep learning models were instrumental in the discovery of Halicin, a potent antibiotic identified from a library of over 6,000 compounds, showing the ability of AI to identify structural motifs that human medicinal chemists might overlook [18].

Table 2. Scientific Platforms and AI Tools in Drug Discovery

Platform	Developer	AI Technology	Achievement / Utility in Pharmacy
AlphaFold 2	Google DeepMind	Deep Learning / Transformers	Highly accurate prediction of 3D protein structures from amino acid sequences.
AtomNet	Atomwise	Convolutional Neural Networks	Identified potential Ebola treatments by screening existing libraries in <24 hours.
DeepChem	Open-source (Stanford)	Python-based Deep Learning	Python library for molecular modeling, simplifying the application of DL to chemistry.
eToxPred	Academic Research	Machine Learning	Accurate prediction of compound toxicity to reduce late-stage clinical attrition.
IBM Watson for Oncology	IBM	Natural Language Processing	Analyzes vast oncology literature to suggest personalized treatment protocols.



Figure 1. The AI-Enhanced Drug Discovery Lifecycle

3.1.2. Predictive Toxicology and ADME Profiling

Pre-clinical failure due to toxicity is a major hurdle in drug development. AI platforms like eToxPred and various machine learning models now provide robust predictions of Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) profiles. These systems analyze quantitative structure-activity relationship (QSAR) data to forecast hepatotoxicity, cardiotoxicity, and mutagenicity before a compound enters in vivo testing, thereby prioritizing safer candidates and reducing the ethical and financial burden of animal experimentation [4, 19].

3.2. Clinical Pharmacy and Intelligent Decision Support

In the clinical environment, AI serves as a critical layer of safety and optimization, augmenting the pharmacist's ability to manage complex medication regimens.

3.2.1. Real-Time Clinical Decision Support Systems (CDSS)

Intelligent CDSS utilize patient-specific data, including lab results, comorbidities, and current prescriptions, to provide real-time alerts. These systems are designed to detect subtle drug-drug interactions, identify contraindications, and suggest therapeutic alternatives. Beyond simple rule-based alerts, modern CDSS employ predictive analytics to identify patients at high risk for medication-related problems, such as acute kidney injury or hospital readmission, allowing for proactive pharmacist intervention [12].



Figure 2. Computational Ecosystem of Clinical Pharmacy Decision Support

3.2.2. Automated Pharmacovigilance and Safety Monitoring

The identification of Adverse Drug Reactions (ADRs) traditionally relied on passive reporting, which is often delayed or incomplete. AI models now perform active pharmacovigilance by scanning electronic health records and social media datasets for linguistic patterns associated with side effects. This real-time monitoring enables the early detection of safety signals, significantly enhancing the speed at which regulatory bodies and clinicians can respond to emerging risks [14].

3.3. Precision Medicine and Pharmacogenomic Integration

The shift toward personalized medicine is driven by the ability of AI to integrate genomic data with clinical outcomes to tailor therapy to the individual.

3.3.1. Genomic Data Interpretation and Phenotype Prediction

Pharmacogenomics requires the analysis of vast arrays of single nucleotide polymorphisms (SNPs) and their influence on drug metabolism. AI algorithms, particularly those based on deep learning, are uniquely suited to handle this complexity, predicting how specific genetic variations will impact an individual's response to anticoagulants, antiplatelets, or chemotherapeutic agents. This ensures that the "right drug" is given at the "right dose" based on the patient's unique biological blueprint [11, 20].

3.3.2. Optimization of Therapeutic Outcomes

AI can predict the long-term efficacy of a treatment plan by analyzing longitudinal patient data. This includes modeling the progression of chronic diseases and adjusting therapeutic strategies before a patient experiences clinical decline. This proactive approach to pharmaceutical care minimizes the trial-and-error period often associated with managing conditions like hypertension, diabetes, or depression [6].

3.4. Pharmaceutics and Sophisticated Formulation Design

The transition from empirical formulation to computational design has enabled the development of highly specialized drug delivery systems.

3.4.1. Artificial Neural Networks in Formulation Optimization

Artificial Neural Networks (ANNs) are utilized to model the intricate interactions between active pharmaceutical ingredients (APIs) and excipients. In graduate research, these models allow students to predict critical quality attributes such as disintegration time, dissolution rates, and mechanical strength without the need for exhaustive laboratory batches. This multi-objective optimization ensures that the final dosage form meets stringent regulatory requirements for bioavailability and stability [17].



Figure 3. Neural Network for Formulation Optimization

Table 3. Comparison of Traditional Empirical Pharmaceutics vs. Computational Pharmaceutics

Parameter	Traditional Empirical Approach	AI-Driven Computational Approach	Impact on Pharmaceutical Outcome
Methodology	Trial-and-error based on researcher experience.	Multi-objective optimization via Neural Networks (ANN).	Significant reduction in laboratory waste and time-to-market.
Data Handling	Manual observation of limited variables.	High-throughput analysis of non-linear variables.	Identification of complex excipient-API interactions.
Formulation Stability	Real-time stability testing over months/years.	Predictive stability modeling using accelerated data.	Earlier prediction of shelf-life and degradation pathways.
Dosage Design	Standardized mass-production (Tablets/Capsules).	Customized 3D printing and digital geometry.	Precise modulation of drug release profiles (e.g., zero-order).

3.4.2. 3D Printing and Digital Manufacturing

AI plays a pivotal role in the design of 3D-printed pharmaceuticals, where dosage forms can be customized in terms of geometry and internal architecture. Computational models predict the printing parameters required to achieve specific release profiles, such as zero-order or pulsatile release. This technology paves the way for "polypills" that combine multiple medications into a single, custom-shaped tablet, significantly improving adherence for patients with complex medication schedules [2, 14].

4. Pharmacy Operations and Intelligent Automation

Beyond clinical analysis, computational intelligence is fundamentally restructuring the operational logistics of pharmacy practice, particularly within hospital and large-scale retail environments.

4.1. Robotic Dispensing and High-Fidelity Fulfillment

The integration of robotic systems in medication dispensing has significantly mitigated the risks associated with manual processing. Modern robotic platforms utilize machine vision and integrated barcode verification to pick, package, and label medications with a degree of precision that exceeds human capability. Systems implemented in major medical centers have showed the ability to process hundreds of thousands of doses with near-zero error rates, thereby enhancing patient safety while allowing pharmacists to transition from technical tasks to high-value clinical interventions [8, 12].

4.2. Algorithmic Inventory and Supply Chain Management

Predictive analytics are now employed to optimize the pharmaceutical supply chain. AI models can forecast medication demand with high accuracy by analyzing historical consumption patterns alongside real-time epidemiological data. This prevents both the depletion of critical life-saving drugs and the financial loss associated with the expiration of overstocked inventory. Integrated supply chain tracking ensures the authenticity of the medication, providing a robust defense against the entry of counterfeit products into the healthcare system [2, 15].



Figure 4. The Intelligent Pharmacy Automation & Supply Chain Loop

5. Impact on Graduate Pharmacy Education and Career Trajectories

As AI becomes a cornerstone of pharmaceutical science, the academic framework for graduate education must undergo a rigorous transformation to maintain professional relevance.

5.1. Curriculum Modernization and Digital Literacy

Current graduate programs are increasingly incorporating coursework in bioinformatics, health informatics, and the ethical use of algorithms. This pedagogical shift ensures that students are not merely passive users of technology but are capable of interpreting AI-generated insights and identifying the limitations of automated systems. Virtual patient simulations and AI-driven case scenarios provide a risk-free environment for students to hone their clinical reasoning, bridging the gap between theoretical knowledge and practical application [12, 14].

5.2. Emerging Professional Roles and Career Readiness

The digital transformation of pharmacy is creating novel career pathways. Graduates with expertise in AI are uniquely positioned to serve as clinical data scientists, digital health consultants, and innovation specialists within the pharmaceutical industry. These roles require a synergy between traditional pharmacotherapy and advanced computational skills, enabling pharmacists to lead the development of digital therapeutics and intelligent health monitoring platforms [13].

6. Ethical and Regulatory Guidelines

The deployment of AI in healthcare necessitates a robust ethical and regulatory dialogue to ensure that technological advancement does not compromise patient welfare.

6.1. Algorithmic Bias and the Principle of Justice

One of the primary ethical challenges is the potential for algorithmic bias. If the datasets used to train AI models are not representative of diverse patient populations, the resulting recommendations may exacerbate existing health disparities. It is

imperative that developers and clinicians work collaboratively to audit algorithms for fairness and ensure that the benefits of computational intelligence are distributed equitably across all demographic groups [14, 21].

Table 5. Barriers and Ethical Constraints in Pharmaceutical AI Integration

Ethical / Operational Barrier	Description of Challenge	Mitigation Strategy
Algorithmic Bias	Training data skewed toward specific demographics.	Utilization of diverse, multi-ethnic datasets for model training.
Data Privacy	Vulnerability of sensitive patient genomic data.	Implementation of Federated Learning and Blockchain encryption.
Black-Box Nature	Lack of transparency in deep learning decision logic.	Development of Explainable AI (XAI) to provide clinical rationales.
Regulatory Lag	FDA/EMA guidelines trailing behind technical innovation.	Development of dynamic regulatory frameworks for software-as-a-medical-device (SaMD).
Interoperability	Siloed data across different hospital systems.	Adoption of standardized data formats (e.g., FHIR) for seamless exchange.

6.2. Data Privacy and the Preservation of the Human Element

The reliance on vast repositories of patient data for AI training raises significant concerns regarding confidentiality and security. Robust encryption and stringent access controls are essential to protect sensitive health information. While AI can optimize technical processes, it cannot replicate the empathy and nuanced communication essential to the pharmacist-patient relationship. Professional practice must remain "human-centric," where AI acts as a sophisticated tool under the oversight of a qualified practitioner [12, 16].

7. Conclusion

Artificial Intelligence is no longer a peripheral technology but a fundamental driver of innovation in pharmaceutical research, education, and clinical practice. AI allows pharmacists to elevate their role as clinical experts and patient advocates by automating routine operations and providing deep analytical insights into drug behavior and patient response. The successful usage of these technologies depends on a proactive approach to education, a commitment to ethical standards, and a continuous dialogue between the pharmaceutical and computational sciences. The synergy between human expertise and algorithmic intelligence will define the future of therapeutic excellence as the healthcare becomes increasingly digitized.

References

[1] Mak KK, Pichika MR. Artificial intelligence in drug development: Present status and future prospects. Drug Discov Today. 2019;24(3):773–780.

[2] Hassanzadeh P, Atyabi F, Dinarvand R. The significance of artificial intelligence in drug delivery system design. Adv Drug Deliv Rev. 2019;151:169–190.

[3] Russell S, Dewey D, Tegmark M. Research priorities for robust and beneficial artificial intelligence. AI Mag. 2015;36(4):105–114.

[4] Duch W, Setiono R, Zurada JM. Computational intelligence methods for rule-based data understanding. Proc IEEE. 2004;92(5):771–805.

[5] Dasta JF. Application of artificial intelligence to pharmacy and medicine. Hosp Pharm. 1992;27(4):319–322.

[6] Jiang F, Jiang Y, Zhi H, et al. Artificial intelligence in healthcare: Past, present and future. Stroke Vasc Neurol. 2017;2(4):230–243.

[7] Gobburu JV, Chen EP. Artificial neural networks as a novel approach to integrated pharmacokinetic–pharmacodynamic analysis. J Pharm Sci. 1996;85(5):505–510.

[8] Aungst TD, Belliveau P. The potential of artificial intelligence in pharmacy practice. Am J Health Syst Pharm. 2021;78(21):1930-1933.

[9] Marwitz KK. The pharmacist's active role in combating COVID-19 medication misinformation. J Am Pharm Assoc. 2021;61(2):e71–e74.

[10] Jorjes F, et al. The rise of telepharmacy services during the COVID-19 pandemic: A comprehensive assessment. J Pharm Health Serv Res. 2021;12(3):412-420.

[11] Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793–795.

[12] Pedersen CA, Schneider PJ, Scheckelhoff DJ. ASHP national survey of pharmacy practice in hospital settings: Prescribing and transcribing—2016. Am J Health Syst Pharm. 2017;74(17):1336–1352.

[13] Kumar S, Gage B. The role of artificial intelligence in managing medication adherence. J Pharm Pract. 2014;27(3):250–256.

[14] Miotto R, et al. Deep learning for healthcare: review, opportunities and challenges. Brief Bioinform. 2018;19(6):1236–1246.

[15] Clauson KA, et al. Leveraging blockchain technology in personalized medicine and pharmacy. J Med Syst. 2018;42(1):16.

[16] Challen R, et al. Artificial intelligence, bias and clinical safety. BMJ Qual Saf. 2019;28(3):231-237.

[17] Paranjape K, et al. Introducing artificial intelligence training in medical education. JMIR Med Educ. 2019;5(2):e16048.

[18] Koster A, et al. Artificial intelligence in pharmacy education: A systematic review. Am J Pharm Educ. 2022;86(5):8865.

[19] Tsao NW, et al. The impact of a closed-loop electronic medication management system on medication errors. J Am Pharm Assoc. 2014;54(6):597-604.

[20] Seidling HM, et al. Impact of a drug-drug interaction screening system on alert sensitivity. J Am Med Inform Assoc. 2011;18(Suppl 1):i191-i196.

[21] Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44-56.